Hallmarks of T-cell exhaustion and antigen experience are absent in multiple myeloma from diagnosis to maintenance therapy

C Carolyn Shasha (1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA) D David R. Glass (1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA) E Ernest Moelhman (1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA) L Laura Islas (1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA) Y Yuan Tian T Tony Chour (1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA) G Guoyue Xu (1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA) G Gregory L. Szeto (3Allen Institute for Immunology, Seattle, WA) T Tao Peng X Xiaoling Song (3Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, WA) M Michelle Wurscher (1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA) A Andrew J. Cowan T Thomas F. Bumol T Troy R. Torgerson P Philip D. Greenberg D Damian J. Green E Evan W. Newell (Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center)

Abstract

Abstract Dysregulation of the bone marrow (BM) niche in multiple myeloma (MM) alters the composition and state of resident immune cells, potentially impeding antitumor immunity. One common mechanism of immune inhibition in solid tumors is the induction of exhaustion in tumor-specific T cells. However, the extent of T-cell exhaustion is not well characterized in MM. As the specific mechanisms of immune evasion are critical for devising effective therapeutic strategies, we deeply profiled the CD8+ T-cell compartment of patients with newly diagnosed MM (NDMM) for evidence of T-cell activation and exhaustion. We applied single-cell multiomic sequencing and mass cytometry to longitudinal BM and peripheral blood (PB) samples taken from time points spanning from diagnosis to induction therapy, autologous stem cell transplant, and maintenance therapy. We identified an exhausted-like population that lacked several canonical exhaustion markers, was not significantly enriched in patients with NDMM, and consisted of small, nonpersistent clonotypes. We also observed an activated population with increased frequency in the PB of patients with NDMM exhibiting phenotypic and clonal features consistent with homeostatic, cytokine-driven activation. As an orthogonal measurement of T-cell exhaustion, we performed intracellular cytokine staining and found that patients with NDMM lacked functionally exhausted T cells. In summary, there was no evidence of “tumor-experienced” T cells displaying hallmarks of terminal exhaustion and/or antigen-driven activation/expansion in patients with NDMM at any time point.

Article Details

Journal Blood
Volume / Issue Vol. 145, Issue 26
Published June 26, 2025
Pages 3113-3123
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (17)

C

Carolyn Shasha

1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA

D

David R. Glass

1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA

E

Ernest Moelhman

1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA

L

Laura Islas

1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA

Y

Yuan Tian

T

Tony Chour

1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA

G

Guoyue Xu

1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA

G

Gregory L. Szeto

3Allen Institute for Immunology, Seattle, WA

T

Tao Peng

X

Xiaoling Song

3Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, WA

M

Michelle Wurscher

1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA

A

Andrew J. Cowan

T

Thomas F. Bumol

T

Troy R. Torgerson

P

Philip D. Greenberg

D

Damian J. Green

E

Evan W. Newell

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center